Mario Rovirosa Escosura

SABA - Aparcamientos de Barcelona SA constructs, operates and sells car parks, garages and service stations. It also manages car parks under concession from the public administration, leases parking spaces for third parties and manages parking spaces in the real estate market. The group has subsidiaries in Spain and abroad, such as Saba Aparcaments SA, Societat d'Aparcaments de Terrassa SA, Parbla SL, Sociedade de Parques de Estacionamento SA, Saba Italia SA, Rabat Parking SA and Saba Estacionamiento de Chile SA. SABA SA was founded in 1966 and is headquartered in Barcelona, Spain.

Saba Infraestructuras SA engages in providing urban mobility solutions. It offers car park management and car park remodeling services. The firm focuses on administrative concessions, ownership, and rental and management. The company was founded in 2011 and is headquartered in Barcelona, Spain.

Saba Aparcamientos SA is a parking facilities company. It is engaged in owning, building, operating, maintaining and managing car parks. The company was founded on December 7, 1965 and is headquartered in Barcelona, Spain.

Otsuka Pharmaceutical Europe Ltd. markets drugs, nutraceuticals and other health care products manufactured by its Japan-based parent, Otsuka Pharmaceutical. Some of the company's nutraceutical products include Pocari Sweat-electrolyte replacement beverages, Calorie Mate-energy beverages and the Calcium. Otsuka also makes products for infants under the Bean Stalk name. Additionally, the company conducts pharmaceutical research focusing on gastroenterology, oncology, dermatology, ophthalmology and the cardiovascular system. The company was founded in 1998 and is headquartered in Uxbridge, UK

Caixa Capital Risc SGEIC SA (Caixa Capital Risc) is a venture capital armof Criteria Caixa SA founded in 2002. The firm is headquartered in Barcelona, Spain with additional offices in Madrid.

GlyCardial Diagnostics SL has developed a biomarker called iSCOR that can detect cardiac ischemia through a blood test. The company is based in Barcelona, Spain. Early detection of ischemia can prevent myocardial damage. The Spanish company was founded in 2017 by Rafols Judit Cubedo, Lina Badimon Maestro, Capmany Teresa Padro, and Gemma Vilahur. Rafols Judit Cubedo has been the CEO since 2017.

Inbiomotion SL designs and develops diagnostic assays. It focus on genetic biomarkers, which predict the bone-specific metastases in cancer patients. The firm develops biomarker in breast cancer primary tumors for predicting the bone relapse. The company was founded by in 2010 and is headquartered in Barcelona, Spain.